Table 3. Progression free and overall survival from the adjusted Cox proportional hazards models on 111 PD-L1 <50% NSCLC patients (pts) stratified according to clinical and molecular scores individually and integrated into the DEMo score system.
| Model_2 | pts | Progression free survival | Overall survival | |||||
|---|---|---|---|---|---|---|---|---|
| HR* | 95% CI | P value | HR* | 95% CI | P value | |||
| Di Maio | ||||||||
| DiM_1 | 37 | 0.26 | 0.13–0.54 | 0.0003 | 0.36 | 0.20–0.67 | 0.0012 | |
| DiM_2&3 | 74 | 1 (ref) | – | – | 1 (ref) | – | – | |
| EPSILoN | ||||||||
| E_1 | 25 | 0.43 | 0.22–0.85 | 0.0148 | 0.55 | 0.31–0.99 | 0.0451 | |
| E_2&3 | 86 | 1 (ref) | – | – | 1 (ref) | – | – | |
| MSC risk level | ||||||||
| Low/intermediate | 64 | 0.57 | 0.36–0.91 | 0.0177 | 0.73 | 0.48–1.12 | 0.1495 | |
| Othersǂ | 47 | 1 (ref) | – | – | 1 (ref) | – | – | |
| DEMo score | ||||||||
| 3 | 12 | 0.21 | 0.07–0.62 | 0.0049 | 0.28 | 0.12–0.65 | 0.0031 | |
| 4 to 9 | 99 | 1 (ref) | – | – | 1 (ref) | – | – | |
*, adjusted for age, sex, pack-year, line of therapy and ECOG performance status; ǂ, patients with high MSC risk level or undetermined results were included. NSCLC, non-small cell lung cancer; MSC, microRNA signature classifier; HR, hazard ratio; CI, confidence interval; ref, reference.